repository
BROWSE
Cited 0 times in 
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
- Authors
- Kim, HA | Lee, JW | Nam, SJ | Park, BW | Im, SA | Lee, ES | Jung, YS | Yoon, JH | Kang, SS | Lee, SJ | Park, KH | Jeong, J | Cho, SH | Kim, SY | Kim, LS | Moon, BI | Lee, MH | Kim, TH | Park, C | Jung, SH | Gwak, G | Kim, J | Kang, SH | Jin, YW | Kim, HJ | Han, SH | Han, W | Hur, MH | Noh, WC | Korean Breast Cancer Study Group
- Citation
- Journal of clinical oncology, 38(5). : 434-443, 2020
- Journal Title
- Journal of clinical oncology
- ISSN
- 0732-183X1527-7755
- Abstract
- PURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age
- MeSH
- PMID
- 31518174
- Appears in Collections:
- Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
